(Q46543501)

23 December 2017

title

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma (English)

1 reference

23 December 2017

1 reference

2

Brian G M Durie

1 reference

23 December 2017

author name string

Sundar Jagannath

1

1 reference

23 December 2017

Jeffrey Wolf

3

1 reference

23 December 2017

Elber Camacho

4

1 reference

23 December 2017

David Irwin

5

1 reference

23 December 2017

Jose Lutzky

6

1 reference

23 December 2017

Marti McKinley

7

1 reference

23 December 2017

Eli Gabayan

8

1 reference

23 December 2017

Amitabha Mazumder

9

1 reference

23 December 2017

David Schenkein

10

1 reference

23 December 2017

John Crowley

11

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

23 December 2017

British Journal of Haematology

published in

1 reference

23 December 2017

volume

129

1 reference

23 December 2017

page(s)

776-783

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

Single versus double autologous stem-cell transplantation for multiple myeloma.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Management of multiple myeloma: a systematic review and critical appraisal of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Bortezomib and its role in the management of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05540.X

10.1111/J.1365-2141.2005.05540.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

15953004

1 reference

23 December 2017